Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03935685
Other study ID # 20194907
Secondary ID UCI 18-83
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date February 26, 2019
Est. completion date December 31, 2024

Study information

Verified date May 2024
Source University of California, Irvine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to estimate the ability of mirtazapine to reduce depression, nausea, and vomiting, and maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Of equal importance, the investigators will monitor the tolerability of Mirtazapine in these patients over the course of the study.


Description:

Research Hypothesis: For glioma patients undergoing TMZ chemotherapy, Mirtazapine will address TMZ-associated nausea and vomiting (CINV) and weight loss in addition to depression. Mirtazapine acts as an antagonist at the 5-HT3 receptor, which may explain its anti-emetic properties. Mirtazapine is also an appetite stimulant, which may help curb the weight loss associated with TMZ chemotherapy. Specific aim 1: To administer the Beck Depression Inventory to approximately 100 patients meeting the inclusion/exclusion criteria in order to identify at least 36 with clinical depression (defined as total score >= 21). Specific aim 2: To put at least 36 clinically depressed patients identified in aim one on mirtazapine for eight weeks. Specific aim 3: To administer the Beck Depression Inventory to patients from aim two at four weeks and at eight weeks of treatment with mirtazapine. Specific aim 4: To document weight and frequencies of nausea, vomiting, and insomnia among participants over the course of the study. Specific aim 5: To document adverse events experienced by participants over the course of the study and determine, to the extent possible, if mirtazapine is the cause. The investigators will: 1. Assess changes in the distribution of depression scores as measured by the Beck Depression Inventory (a self-administered instrument extensively used and validated in glioma studies) from baseline to after eight weeks of treatment with mirtazapine. 2. Assess changes in nausea, vomiting, Sleeping and body weight between baseline and the eight-week follow-up visit, 3. Document the trajectory of changes in depression, nausea, vomiting, and weight over the three study time points (baseline, four-week, and eight-week visit). 4. Lastly, collect information on the tolerability of mirtazapine in our patient population. Main Research Hypothesis: The investigators hypothesize that the mirtazapine regimen will improve depression scores at eight-weeks, compared to baseline scores. Further, the investigators hypothesize that the mirtazapine regimen will limit the reduction of weight and the incidence of nausea/vomiting and insomnia at eight weeks compared to baseline.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Understand and voluntarily sign and date an informed consent document prior to any study related assessments/procedures are conducted. - Histologically confirmed diagnosis of glioma - No prior treatment with temozolomide TMZ - Patient will receive temozolomide TMZ therapy as part of their standard treatment. - Males and Females =18 years of age at the time of signing the informed consent document. Able to understand consent forms and study materials in English - Willing to use approved methods of contraception for duration of study - Karnofsy Performance Score (KPS) of at least 60 - Patients should have stopped any anti-depressant medications by standard of care at least a month before enrolling in the trial - Willing and able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: - Prior treatment with other chemotherapy drugs for glioma - Known hypersensitivity to Mirtazapine and 5-HT3 receptor antagonists - Life expectancy of less than three months - Pregnancy or breastfeeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mirtazapine (Remeron)
Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.

Locations

Country Name City State
United States UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Irvine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Depression level in glioma patients on temozolomide therapy treated with Mirtazapine The assessment is conducted using the Beck Depression Inventory. The scoring scale ranges from 1 to 63. Participants with a baseline depression score of 21 or more will be classified as depressed and will be issued a prescription for mirtazapine. Total depression score between baseline and eight weeks will be compared for each patient. Distributional properties of the data will be assessed using appropriate statistical method to examine whether there is statistically significant improvement or not. 8 weeks
Primary Patient Weight Change To estimate the ability of mirtazapine to maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Weight change for each patient between baseline and 8 week will be calculated and analyzed using applicable statistical method. 8 weeks
Primary Frequency and grade of nausea and vomiting in depressed glioma patients on temozolomide therapy treated with Mirtazapine To assess the patient's level of nausea and vomiting on a nausea/vomiting scale of 1 to 7. Lower value indicates less nausea and vomiting; while higher value indicates more nausea and vomiting. Data will be assessed using appropriate statistical method to examine whether there is statistically significant improvement or not. 8 weeks
Primary Incidence of Treatment-Emergent Adverse Events To monitor the adverse event of Mirtazapine over the course of the study. AEs will be graded according to CTCAE V5. 8 weeks
Secondary Percentage of adherence to mirtazapine regimen The percentage will be calculated based on patient's pill diary entries. Higher percentage indicates patient is more compliant. 8 weeks
Secondary Frequency of dose modifications of mirtazapine The dose of mirtazapine can be adjusted based on patients' conditions and adverse event reports per protocol. This is defined as the number of times that the mirtazapine dose has to be modified for each patient. 8 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT03796507 - Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation Early Phase 1
Withdrawn NCT04406610 - CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients Phase 1/Phase 2
Active, not recruiting NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma Phase 1/Phase 2
Active, not recruiting NCT03189420 - Glioma Microenvironment an Exploratory Study
Completed NCT03194906 - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Phase 2
Active, not recruiting NCT03739372 - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma N/A
Completed NCT03779230 - Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse Phase 1/Phase 2
Recruiting NCT03728673 - A Study Utilizing Escitalopram in Glioma Patients Phase 2
Active, not recruiting NCT03496181 - Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
Recruiting NCT03180697 - The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas N/A
Recruiting NCT03949192 - Efficacy of Kangliuwan for Recurrent Grade IV Glioma
Terminated NCT03927274 - Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma Early Phase 1
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Not yet recruiting NCT03763396 - Azoles Targeting Recurrent High Grade Gliomas Early Phase 1
Terminated NCT03698201 - Blood Biomarker Signature in Glioma
Terminated NCT03436433 - Seizure Prophylaxis in Patients With Glioma or Brain Metastasis Phase 2
Recruiting NCT03750890 - Visual Study of Molecular Genotype in Glioma Evolution
Enrolling by invitation NCT03102112 - Noninvasively Predicting Gene Status of Glioma N/A
Completed NCT03834740 - A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection Early Phase 1
Recruiting NCT03849430 - Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients